Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia

被引:8
作者
Carbon, C
van Rensburg, D
Hagberg, L
Fogarty, C
Tellier, G
Rangaraju, M
Nusrat, R
机构
[1] Medpark Ctr, ZA-1035 Witbank, South Africa
[2] Sahlgrens Univ Hosp, S-41685 Gothenburg, Sweden
[3] Spartanburg Pharmaceut Res, Spartanburg, SC 29307 USA
[4] Zoom Int Clin Res Grp, St Jerome, PQ J7Z 5T3, Canada
[5] Sanofi Aventis, Romainville, France
[6] Sanofi Aventis, Bridgewater, NJ USA
关键词
telithromycin; community-acquired pneumonia; bacteremia; sepsis; ketolide; Streptococcus pneumoniae;
D O I
10.1016/j.rmed.2005.11.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This retrospective analysis was performed to determine the clinical and bacteriologic efficacy of the ketolide antibacterial telithromycin in patients with community-acquired pneumonia (CAP) with pneumococcal bacteremia. Patients >= 13 years old with radiologically confirmed CAP and a positive blood culture for Streptococcus pneumoniae at screening were analyzed from eight multicenter Phase III/IV clinical trials. In four open-label, non-comparative studies, patients received telithromycin 800 mg once daily for 7-10 days. In four randomized, controlled, double-blind, comparative studies, patients received telithromycin 800mg once daily for 5-10 days or a comparator antimicrobial (amoxicillin 1000 mg three times daily, clarithromycin 500mg twice daily, or trovafloxacin 200mg once daily) for 7-10 days. In total, 118 patients (telithromycin, 94/1061 [8.9%]; comparator, 24/244 [9.8%]) had documented pneumococcal bacteremia. Those who were treated with telithromycin achieved a clinical cure rate of 90.2% (74/82, per-protocol population); S. pneumoniae was eradicated in 77/82 (93.9%) bacteremic patients who received telithromycin and 15/19 (78.9%) comparator-treated patients. Clinical cure was also observed among telithromycin-treated bacteremic patients who were infected with penicillin- or erythromycin-resistant strains of S. pneumoniae (5/7 and 8/10, respectively). In conclusion, telithromycin achieves high clinical and bacteriologic cure rates in CAP patients with pneumococcal bacteremia. (c) 2005 Published by Elsevier Ltd.
引用
收藏
页码:577 / 585
页数:9
相关论文
共 45 条
  • [1] [Anonymous], 1997, MMWR Recomm Rep, V46, P1
  • [2] Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults
    Aubier, M
    Verster, R
    Regamey, C
    Geslin, P
    Vercken, JB
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (06) : 1312 - 1320
  • [3] Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia
    Baddour, LM
    Yu, VL
    Klugman, KP
    Feldman, C
    Ortqvist, A
    Rello, J
    Morris, AJ
    Luna, CM
    Snydman, DR
    Ko, WC
    Chedid, MBF
    Hui, DS
    Andremont, A
    Chiou, CCC
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (04) : 440 - 444
  • [4] Balfour JAB, 2001, DRUGS, V61, P815
  • [5] Evolving resistance patterns of Streptococcus pneumoniae:: A link with long-acting macrolide consumption?
    Baquero, F
    [J]. JOURNAL OF CHEMOTHERAPY, 1999, 11 : 35 - 43
  • [6] BAQUERO F, 1998, CLIN MICROBIOL INFEC, V4, P19
  • [7] Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
  • [8] Seven-year study of bacteraemic pneumonia in a single institution
    Bishara, J
    Leibovici, L
    Ashkenazi, S
    Samra, Z
    Pitlik, S
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (12) : 926 - 931
  • [9] *BTS, 2001, THORAX S4, V56, pIV1
  • [10] The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia - A prospective observational study
    Campbell, SG
    Marrie, TJ
    Anstey, R
    Dickinson, G
    Ackroyd-Stolarz, S
    [J]. CHEST, 2003, 123 (04) : 1142 - 1150